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OBJECTIVES:To validate a software, for an optical pencil toll, to
calculate psoriasis patients’ Body Surface Area (BSA) and to
demonstrate that the new developed method is been valid and
reliable to quantify the BSA.METHODS:Multicentre prospective
study at Dermatology centres (Five Spanish Hospitals and one
Portuguese Hospital). In each hospital two dermatologists visited
the same patients twice (second visit 3 days after ﬁrst). 60 derma-
tologists included10 consecutive patients with psoriasis. Socio-
demographical and clinical variables (PASI, time since diagnosis,
current treatment) and BSA scoreswere colleted for each patient in
the two visits. To calculate BSA scores traditional method (visual
grading following the nine rule of Wallace method’s) and the
optical pencil method (BSA software developed) were used. Inter-
intraobservers reliability, variability between BSA scores regard-
ing the new tool, versus the traditional method, and the tool’s
usefulness will be assessed. RESULTS: Fifty-six patients were
included.Mean (SD) agewas 48.93 (16.76) years.Mean (SD) time
since diagnosis was 18.77 (14.28). Pearson’s correlation coefﬁ-
cient between both methods was 0.91 (p < 0.01). Intraobserver
correlation for each of the methods was 0.91. The correlation
among both methods was in the ﬁrst visit 0.92 and 0.90 in the
second visit. The ICC was higher than 0.85 independently of
which of the two methods were used ﬁrstly. The investigators
considered that the new method is easy to use (94%), it guides
towards the disease management (64%) and standardizes the
calculation of the body surface area (86.4%). CONCLUSION:
These results can prove that the software to assess BSA has shown
to be valid to be used both in clinical practice and in clinical
studies. Therefore, the optical pencil method to quantify BSA can
be used as standard for the assessment of involved body surface
area in the management of psoriatic patients.
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OBJECTIVES: The introduction of novel therapeutic options for
psoriasis has raised managed care’s interest in controlling costs
associated with dermatological treatments. Prior authorization
(PA) can be a successful way of managing costs. However, expe-
rience with topical treatments for acne suggests that PA may not
be cost-effective. The role of managed care in dermatology and
the potential impact of PA requirements for novel topical thera-
pies for psoriasis are considered. METHODS: Using a model
based on recent nationally representative survey data (NAMCS),
total annual cost estimates for a managed care organization to
cover psoriasis treatment with a topical agent with or without PA
requirements were calculated and compared. Costs for treatment
and administrative costs associated with PA processes were
included. The model assumed 68,000 insured patients required
treatment (with an additional 1% to account for abuse/misuse),
an average wholesale price of $100 per prescription (each pre-
scription ﬁlled 4x/year), and a cost of $20 to process each PA
request. RESULTS: The total annual costs were $28,573,600
when PA was required and $27,472,000 when PA was not
required. Thus there was a total annual loss to the managed care
organization of $1,101,600 associated with PA requirements.
CONCLUSION: Requiring PA for novel topical treatments for
psoriasis, such as the new 2-compound product containing cal-
cipotriene and betamethasone dipropionate, is not likely to be
cost-effective for a managed care organization.
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OBJECTIVES: In an increasing number of European countries
patient-deﬁned beneﬁt is considered important in the valuation
of therapy. So far, most procedures used for beneﬁt assessment do
not cover the broad spectrum of beneﬁts relevant to patients nor
do they allow for an individual weighting of preferences. In this
context a patient-reported beneﬁt questionnaire was developed
and validated. METHODS: Initially, open questioning of n = 100
dermatological patients generated a pool of 213 beneﬁt items
which were converted into a 24 item-list by an expert panel of
dermatologists, psychologists and patients. This pilot version of
the questionnaire was evaluated in a group of n = 500 patients
with 10 dermatological diagnoses. Basic principle of the instru-
ment is pre/post data-collection. Prior to therapy, individually
perceived needs (Patient Needs Questionnaire, PNQ) are
obtained: For each of the 24 standardized items patients rate its
importance on a Likert scale ranging from 0 (“not important at
all” resp. “doesn’t apply to me”) to 4 (“very important”). At the
end of therapy the degree to wich these beneﬁts (Patient Beneﬁt
Questionnaire, PBQ) were achieved is assessed using the same list
with scaling from 0 (“therapy didn’t help at all”) to 4 (“helped a
lot”). To compose a single outcome parameter a formula was
developed by weighting the PBQ with their respective PNQ-
items. This “Patient Beneﬁt Index” (PBI) also ranges from 0 to 4.
RESULTS: Besides good acceptance and feasibility the PBI
showed construct validity and the PNQ a high internal consis-
tency with Cronbach’s alpha > 0.94. Diagnostic groups presented
different and clinically plausible outcome-patterns: Whereas the
PBI was rather low for all vitiligo-therapies (mean = 1.03, SD
1.13, n = 711) wound-patients undergoing vacuum-assisted
therapy (n = 172) showed a mean PBI of 2.75 (SD = 0.89). CON-
CLUSION: The PBI is a valid and reliable instrument to obtain
patient-deﬁned and individually weighted therapeutic beneﬁts in
clinical and public health studies.
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OBJECTIVES: The Dermatology Life Quality Index (DLQI) is a
validated and widely used patient reported outcomes instrument.
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